The surge in prescriptions for GLP-1 receptor agonists—including medications like Ozempic, Wegovy, and Mounjaro—has brought unprecedented weight loss results to millions. However, as these drugs develop into staples of modern metabolic health, clinicians are documenting a series of unconventional side effects that go far beyond the well-known nausea and gastrointestinal distress.
One of the most striking, and physically unsettling, is what some describe as a human “hairball.” Whereas the term is a colloquialism, the medical reality is a condition known as a phytobezoar: a dense mass of indigestible plant fibers that can accumulate in the stomach, potentially growing to the size of a tennis ball.
This hairball side effect of weight loss drugs is a direct consequence of how GLP-1 medications function. By design, these drugs gradual gastric emptying—the rate at which food leaves the stomach and enters the slight intestine—to support patients sense full longer and reduce caloric intake. However, when digestion slows significantly, indigestible materials can linger too long, coalescing into a solid blockage.
Dr. Karl Kruszelnicki, a prominent Australian scientist and physician, recently highlighted this phenomenon, noting that while humans do not develop hairballs in the same way cats do, the resulting phytobezoars create a similar obstructive effect. He explained that this occurs when the fibrous parts of vegetables stay stuck in the stomach and build up into a ball of material.
The Chemistry of the ‘Cola Cure’
For many patients, a phytobezoar can cause significant abdominal pain and a feeling of premature fullness. Historically, the primary medical intervention was invasive: an endoscopic procedure where a physician slides a tube with blades down the throat to physically chop up the blockage.
However, more recent observations suggest a less invasive alternative. According to Dr. Kruszelnicki, researchers have found that regular black cola drinks can be effective in dissolving these masses. The efficacy lies in the chemistry of the beverage; specifically, the presence of carbonic acid and phosphoric acid helps break down the fibrous structure of the bezoar.
This approach is not entirely new to gastroenterology. Patients with certain types of bowel obstructions or those with stomas have long used cola as a first-line attempt to clear blockages. In the context of GLP-1 drugs, the acidity of the soda acts as a chemical solvent, potentially sparing the patient from surgery or endoscopy.
Despite the anecdotal success of this remedy, medical professionals emphasize that patients should never attempt to self-treat a suspected blockage. Abdominal pain can signal a variety of serious conditions, and a physician’s diagnosis is required to ensure the blockage is a phytobezoar and not a more critical surgical emergency.
Beyond the Gut: Rewiring the Reward System
While the physical blockages are concerning, researchers are equally fascinated by how these medications affect the brain. Most users are familiar with the reduction of “food noise”—the constant, intrusive thoughts about eating. But the influence of GLP-1s appears to extend to other compulsive behaviors.
Evidence suggests that these drugs may dull the drive for various dependence-related behaviors, including alcohol consumption, smoking, and even gambling. This suggests that GLP-1 receptor agonists do more than regulate insulin and hunger; they may fundamentally alter how the brain processes reward.
Dr. Pietro Cottone, co-director of the Laboratory of Addictive Disorders at Boston University, has noted that anecdotal reports show a decreased interest in compulsive activities. He explained that these medications might make people feel less pleasure after engaging in such behaviors, thereby reducing the drive to pursue them.
“Weight-loss medications like GLP-1s don’t just affect hunger and metabolic dysfunction – they influence how the brain processes reward,” Dr. Cottone stated.
Understanding the Risks and Management
As the use of these drugs expands, the medical community is working to establish better screening and management protocols for these rare but disruptive side effects. The risk of phytobezoars is particularly high for those who consume high-fiber diets without adequate hydration, which can exacerbate the slowing of gastric transit.
To mitigate these risks, healthcare providers generally recommend a gradual introduction of fiber and a focus on highly hydrated, softer foods. Monitoring for symptoms such as persistent nausea, vomiting, or severe abdominal tugging is essential for those on a GLP-1 regimen.
| System | Primary Intent | Unexpected Side Effect |
|---|---|---|
| Digestive | Slow gastric emptying | Phytobezoar (fiber blockage) |
| Neurological | Reduce food cravings | Reduced gambling/shopping urges |
| Metabolic | Blood glucose regulation | Altered reward processing |
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication.
The medical community continues to track the long-term implications of GLP-1 therapy. The next major phase of research is expected to focus on whether these drugs can be formally repurposed as treatments for addiction and compulsive disorders, moving beyond their primary role in obesity and diabetes management.
Have you or a loved one experienced unexpected side effects while using weight loss medications? Share your experience in the comments below or reach out to your healthcare provider.
